NASDAQ:TARA Protara Therapeutics (TARA) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free TARA Stock Alerts $3.00 +0.02 (+0.67%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$2.87▼$3.3450-Day Range$2.64▼$4.4052-Week Range$1.04▼$5.24Volume922,419 shsAverage Volume290,105 shsMarket Capitalization$61.77 millionP/E RatioN/ADividend YieldN/APrice Target$26.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Protara Therapeutics alerts: Email Address Protara Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside783.3% Upside$26.50 Price TargetShort InterestBearish5.00% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.30Based on 11 Articles This WeekInsider TradingSelling Shares$94,554 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.56) to ($3.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.44 out of 5 starsMedical Sector767th out of 925 stocksBiological Products, Except Diagnostic Industry130th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingProtara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageProtara Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Protara Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.00% of the outstanding shares of Protara Therapeutics have been sold short.Short Interest Ratio / Days to CoverProtara Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Protara Therapeutics has recently increased by 158.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProtara Therapeutics does not currently pay a dividend.Dividend GrowthProtara Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TARA. Previous Next 2.1 News and Social Media Coverage News SentimentProtara Therapeutics has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Protara Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for TARA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Protara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $94,554.00 in company stock.Percentage Held by Insiders18.40% of the stock of Protara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 38.13% of the stock of Protara Therapeutics is held by institutions.Read more about Protara Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Protara Therapeutics are expected to decrease in the coming year, from ($3.56) to ($3.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protara Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protara Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtara Therapeutics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Protara Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Protara Therapeutics Stock (NASDAQ:TARA)Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.Read More TARA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TARA Stock News HeadlinesMay 11, 2024 | insidertrades.comInsider Selling: Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells 30,600 Shares of StockMay 9, 2024 | americanbankingnews.comHC Wainwright Equities Analysts Decrease Earnings Estimates for Protara Therapeutics, Inc. (NASDAQ:TARA)May 11, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.May 8, 2024 | americanbankingnews.comProtara Therapeutics (NASDAQ:TARA) Stock Rating Reaffirmed by HC WainwrightMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Protara Therapeutics Amid Promising Clinical Trials and Market Potential for TARA-002May 2, 2024 | investorplace.comTARA Stock Earnings: Protara Therapeutics Misses EPS for Q1 2024May 2, 2024 | sfgate.comProtara Therapeutics: Q1 Earnings SnapshotMay 2, 2024 | globenewswire.comProtara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 11, 2024 | The Oxford Club (Ad)Most important medical advance in 100 yearsThis is going to dramatically alter medicine forever. Keep in mind, creating a new effective drug in the past took up to 10 years and could cost up to $12 billion. But now, with artificial intelligence, it could take months and cost a fraction of that amount.April 17, 2024 | msn.comProtara Therapeutics (TARA) Price Target Decreased by 11.76% to 27.54April 15, 2024 | finance.yahoo.comProtara Therapeutics, Inc. (TARA)April 9, 2024 | markets.businessinsider.comBuy Rating for Protara Therapeutics’ TARA-002 Based on Promising Clinical Data and Market Potential in NMIBC TreatmentApril 5, 2024 | msn.comProtara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via EquityApril 5, 2024 | markets.businessinsider.comProtara Reaches Alignment With FDA On A Registrational Path Forward For IV Choline ChlorideApril 5, 2024 | markets.businessinsider.comProtara Announces Positive Data From TARA-002 Trial In Bladder Cancer; Stock UpApril 5, 2024 | globenewswire.comProtara Therapeutics Announces Oversubscribed $45 Million Private Placement FinancingApril 5, 2024 | globenewswire.comProtara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral NutritionApril 5, 2024 | globenewswire.comProtara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBCMarch 23, 2024 | investorplace.com3 Stocks That Could Help You Retire on a Private IslandMarch 13, 2024 | markets.businessinsider.comBuy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market OpportunityMarch 13, 2024 | chron.comProtara Therapeutics: Q4 Earnings SnapshotMarch 13, 2024 | globenewswire.comProtara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 3, 2024 | finance.yahoo.comTARA May 2024 2.500 putMarch 3, 2024 | finance.yahoo.comTARA Aug 2024 7.500 callFebruary 28, 2024 | theglobeandmail.comNon Muscle Invasive Bladder Cancer Pipeline Outlook Report 2024February 28, 2024 | globenewswire.comProtara Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | msn.comNorthSea Therapeutics commences Phase IIa trial for IFALD therapySee More Headlines Receive TARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today5/11/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TARA CUSIPN/A CIK1359931 Webwww.proteontherapeutics.com Phone(646) 844-0337Fax781-487-6729Employees26Year FoundedN/APrice Target and Rating Average Stock Price Target$26.50 High Stock Price Target$30.00 Low Stock Price Target$23.00 Potential Upside/Downside+783.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.80% Return on Assets-51.37% Debt Debt-to-Equity RatioN/A Current Ratio10.53 Quick Ratio10.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.84 per share Price / Book1.06Miscellaneous Outstanding Shares20,590,000Free Float9,330,000Market Cap$61.77 million OptionableOptionable Beta1.80 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Jesse Shefferman (Age 52)Co-Founder, CEO, President & Director Comp: $1.11MDr. Jacqueline Zummo M.B.A. (Age 43)M.P.H., Ph.D., Co-Founder, Senior VP & Chief Scientific Operations Officer Comp: $743.68kDr. Jathin Bandari M.D. (Age 36)Executive Officer Comp: $687.86kMr. Patrick Fabbio M.B.A. (Age 56)Chief Financial Officer Ms. Hannah Fry (Age 33)VP, Principal Accounting Officer & Controller Ms. Justine O'MalleySenior Vice President of Investor Relations & Corporate AffairsMs. Mary J. GrendellGeneral Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsAchilles TherapeuticsNASDAQ:ACHLMiNK TherapeuticsNASDAQ:INKTSurrozenNASDAQ:SRZNPluriNASDAQ:PLURNKGen BiotechNYSE:NKGNView All CompetitorsInsiders & InstitutionsOpaleye Management Inc.Sold 30,600 sharesTotal: $94,554.00 ($3.09/share)Oppenheimer & Co. Inc.Bought 10,000 shares on 5/7/2024Ownership: 0.087%View All Insider TransactionsView All Institutional Transactions TARA Stock Analysis - Frequently Asked Questions Should I buy or sell Protara Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Protara Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TARA shares. View TARA analyst ratings or view top-rated stocks. What is Protara Therapeutics' stock price target for 2024? 2 brokerages have issued 1-year price targets for Protara Therapeutics' stock. Their TARA share price targets range from $23.00 to $30.00. On average, they anticipate the company's share price to reach $26.50 in the next year. This suggests a possible upside of 783.3% from the stock's current price. View analysts price targets for TARA or view top-rated stocks among Wall Street analysts. How have TARA shares performed in 2024? Protara Therapeutics' stock was trading at $1.8751 at the start of the year. Since then, TARA shares have increased by 60.0% and is now trading at $3.00. View the best growth stocks for 2024 here. When is Protara Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our TARA earnings forecast. How were Protara Therapeutics' earnings last quarter? Protara Therapeutics, Inc. (NASDAQ:TARA) issued its quarterly earnings results on Wednesday, March, 13th. The company reported ($0.90) EPS for the quarter, beating analysts' consensus estimates of ($1.03) by $0.13. What other stocks do shareholders of Protara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protara Therapeutics investors own include Immunic (IMUX), Trevena (TRVN), AIM ImmunoTech (AIM), Chimerix (CMRX), CTI BioPharma (CTIC), Fortress Biotech (FBIO), Genocea Biosciences (GNCA) and Otonomy (OTIC). Who are Protara Therapeutics' major shareholders? Protara Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Oppenheimer & Co. Inc. (0.09%). Insiders that own company stock include Jesse Shefferman, Luke M Beshar, Martin Sebastian Olivo and Opaleye Management Inc. View institutional ownership trends. How do I buy shares of Protara Therapeutics? Shares of TARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TARA) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetryThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithMost important medical advance in 100 yearsThe Oxford ClubA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchMissed NVDA? Buy this AI stock NOWChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
